Acknowledgements

O. Karimi received support from the Foundation of Immunogenetics. A.S. Pefia's research in inflammatory bowel disease for 2002-2003 was supported in part by funding from the Crohn's and Colitis Foundation of America (CCFA).

References

  1. Morelli, L. In vitro selection of probiotic lactobacilli: A critical appraisal. Curr Issues Intest Microbiol 2000, 1: 59-67.
  2. Mercenier, A., Pavan, S., Pot, B. Probiotics as biotherapeutic agents: Present knowledge and future prospects. Curr Pharm Des 2003, 9: 175-91 .
  3. Yokokura, T. Lactobacillus casei strain shirota. 1999.
  4. Reid, G. Testing the efficacy of probiotics. En: Tannock, G.w., (Ed.). Probiotics: A critical review Horizon Scientific Press, Wymondham, UK; 1999; ?? 129-140.
  5. Tissier, H. Recherches sur la flore intestinale des nourissons (etat normal et pathologique). Paris, University of Paris; 1906.
  6. Berg, R.D. Probiotics, prebiotics or "conbiotics"? Trends Microbiol 1998, 6: 89-92.
  7. Bengmark, S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998,42: 2-7.
  8. Simmering, R., Blaut, M. Pro- and prebiotics The tasty guardian angels? Appl Microbial Biotechnol 2001, 55: 19-28.
  9. Salminen, S., Isolauri, E., Salminen, E. Clinical uses of probiotics for stabilizing the gut mucosal barrier: Successful strains and future challenges. Antonie Van Leeuwenhoek 1996,70: 347-58.
  10. Yolken, R.H., Ojeh, C., Khatri, lA, Sajjan, U., Forstner, J.F. Intestinal mucins inhibit rota virus replication in an oligosaccharide-dependent manner. J Infect Dis 1994, 169: 1002-6.
  11. Phuapradit, P., Varavithya, W., Vathanophas, K. et al. Reduction of rota virus infection in children receiving bifidobacteria-supplemented formula. J Med Assoc Thai 1999, 82 (Suppl. 1): S43-8.
  12. Marteau, P., Seksik, P., Jian, R. Probiotics and intestinal health effects: A clinical perspective. BrJ Nutr2002, 88 (Suppl. 1): S51-7.
  13. Li, Z., Yang, S., Lin, H. et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37: 343-50.
  14. Cremonini, F., Canducci, F., Di Caro, S. et al. Helicobacter pylori treatment: A role for probiotics? Dig Dis 2001,19: 144-7.
  15. Canducci, F., Cremonini, F., Armuzzi, A. et al. Probiotics and Helicobacter pylori eradication. Dig Liver Dis 2002, 34 (Suppl. 2): S81-3.
  16. Madsen, K.L., Doyle, J.S., Tavernini, M.M., Jewell, LD., Rennie, R.P., Fedorak, R.N. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 2000, 118: 1094-105.
  17. Strober, W., Fuss, I.J., Blumberg, R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002, 20: 495-549.
  18. Dunne, C., O'Mahony, L., Murphy, L. et al. In vitro selection criteria for probiotic bacteria of human origin: Correlation with in vivo findings. Am J Clin Nutr 2001, 73: 386S-392S.
  19. Dunne, C., Murphy, L., Flynn, S., O'Mahony, L. et al. Probiotics: From myth to reality Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van t Leeuwenhoek 1999, 76: 279-92.
  20. Dunne, C. Adaptation of bacteria to the intestinal niche: Probiotics and gut disorder. Inflamm Bowel Dis 2001, 7: 136-45.
  21. Sanders, ME, Klaenhammer, T.R. Invited review: The scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy Sci 2001,84: 319-31.
  22. Kaila, M., Isolauri, E., Soppi, E., Virtanen, E., Laine, S., Arvilommi, H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992, 32: 141-4.
  23. Bengmark, S., Gianotti, L. Nutritional support to prevent and treat multiple organ failure. World J Surg 1996,20: 474-81.
  24. Sanders, M.E. Considerations for use of probiotic bacteria to modulate human health. J Nutr 2000, 130: 384S-90S.
  25. Vaughan, E.E., Mollet, B., deVos, W.M. Functionality of probiotics and intestinal lactobacilli: Light in the intestinal tract tunnel. Curr Opin Biotechnol 1999, 10: 505-10.
  26. Karimi, 0., Pena, A.S. Clinical aspects of probiotics: News on the horizon. Yakult 2003, in press.
  27. De Simone, C. VSL# 3 A probiotic preparation investigator brochure. 2001.
  28. Rambaud, J.C., Bouhnik, Y, Marteau, P., Pochart P. Manipulation of the human gut microflora. Proc Nutr Soc 1993, 52: 357-66.
  29. O'Sullivan MGTGOSGCC, J.K. Probiotic bacteria: Myth or reality? Trends Food Sci Technol 1992, 3: 309-14.
  30. Patterson, J.A., Burkholder, K.M. Application of prebiotics and probiotics in poultry production. Poult Sci 2003, 82: 627-31.
  31. Perdigon, G., Nader de Macias, ME, Alvarez, S., Oliver, G., Pesce de Ruiz Holgado, A.A. Prevention of gastrointestinal infection using immunobiological methods with 'milk fermented with Lactobacillus casei and Lactobacillus acidophilus. J Dairy Res 1990, 57: 255-64.
  32. Rani, B., Khetarpaul, N. Probiotic fermented food mixtures: Possible applications in clinical anti-diarrhoea usage. Nutr Health 1998, 12: 97-105.
  33. McFarland, L.V. Re: Probiotics and C difficile diarrhea. Am J Gastroenterol 2000, 95: 2128.
  34. Sorokulova, I.B., Kirik, D.L., Pinchuk, II. Probiotics against Campylobacter pathogens. J Travel Med 1997,4: 167-70.
  35. Dembele, T., Obdrzalek, V., Votava, M. Inhibition of bacterial pathogens by lactobacilli. Zentralbl Bakteriol 1998, 288: 395-401.
  36. Barrow, P.A., Brooker, B.E., Fuller, R., Newport, M.J. The attachment of bacteria to the gastric epithelium of the pig and its importance in the microecology of the intestine. J Appl Bacteriol 1980,48: 147-54.
  37. Schiffrin, E.J., Brassart, D., Servin, A.L., Rochat, F., Donnet-Hughes, A. Immune modulation of blood leukocytes
  38. in humans by lactic acid bacteria: Criteria for strain selection. Am J Clin Nutr 1997, 66: 515S-20S.
  39. 38) Madsen, K.L. The use of probiotics in gastrointestinal disease. Can J Gastroenterol 2001, 15: 817-22.
  40. Isolauri, E., Majamaa, H., Arvola, T., Rantala, I., Virtanen, E., Arvilommi, H. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 1993, 105: 1643-50.
  41. Eckmann, L., Kagnoff, M.F., Fierer, J. Intestinal epithelial cells as watchdogs for the natural immune system. Trends Microbiol 1995, 3: 11820.
  42. Romagnani, S., Parronchi, P., D'Elios, M.M. et al. An update on human Th1 and Th2 cells. Int Arch Allergy Immunol 1997, 113: 153-6.
  43. Casini-Raggi, V., Kam, L., Chong, YJ., Fiocchi, C., Pizarro, T.T., Cominelli, F. Mucosal imbalance of IL -1 and IL -1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol1995, 154: 2434-40.
  44. Pefia, A.S. Genetics of inflammatory bowel disease. The candidate gene approach: Suscepti- bility versus disease heterogeneity Dig Dis 1998, 16: 356-63.
  45. McGeehan, G.M., Becherer, J.D., Bast, R.C. et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994, 370: 558-61.
  46. Fabia, R., Ar'Rajab, A, Johansson, M.L. et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993, 54: 248-55.
  47. Malin, M., Suomalainen, H., Saxelin, M., Isolauri, E. Promotion of IgA immune response in patients with Grohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996,40: 137-45.
  48. Ruseler-van Embden, J.G., Schouten, WR., van Lieshout, L.M. Pouchitis: Result of microbial imbalance? Gut 1994, 35: 658-64. 48.lvanova, T, Jekova, M. Preventive role of lyophilic dairy products bulgaricum and biostim. Cancer Lett 1997, 114: 93-5.
  49. Campieri, M., Gionchetti, P. Bacteria as the cause of ulcerative colitis. Gut 2001, 48: 132-5.
  50. Neish, AS., Gewirtz, AT., Zeng, H. et al. Prokaryotic regulation of epithelial responses by inhibition of I-K-B-a ubiquitination. Science 2000, 289: 1560-3.
  51. Ulisse, S., Gionchetti, P., D'Alo, S. et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: Effects of probiotic treatment. Am J Gastroenterol 2001, 96: 2691-9.
  52. Friedman, R., Hughes, A.L. Molecular evolution of the NF-K-B signaling system. Immunogenetics 2002, 53: 964-74.
  53. Farrell, R.J., Peppercorn, M.A. Ulcerative colitis. Lancet 2002, 359: 331-40.
  54. Kruis, W, Schutz, E., Fric, P., Fixa, B., Judmaier, G., Stolte, M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997, 11: 853-8.
  55. Rernbacken, B.J., Snelling, A.M., Hawkey, P.M., Chalmers, D.M., Axon, AT Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999, 354 :635-9.
  56. Faubion, WA., Sandborn, W.J. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad. Gastroenterology 2000; 118: 630-1 .
  57. Fedorak, R.N., Madsen, K. Application of probiotics for GI diseases. 2003 symposium mexico.
  58. Ohashi, Y, Inoue, R., Tanaka, K., Matsuki, T, Umesaki, Y, Ushida, K. Lactobacillus casei strain Shirota-fermented milk stimulates indigenous Lactobacilli in the pig intestine. J Nutr Sci Vitaminol (Tokyo) 2001, 47: 172-6.
  59. Ohashi, Y, Inoue, R., Tanaka, K., Umesaki, Y, Ushida, K. Strain gauge force transducer and its application in a pig model to evaluate the effect of probiotic on colonic motility J Nutr Sci Vitaminol (Tokyo) 2001, 47: 351-6.
  60. Shida, K., Takahashi, R., Iwadate, E. et al. Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and immunoglobulin G 1 responses and systemic anaphylaxis in a food allergy model. Clin Exp Allergy ,2002, 32: 563-70.
  61. Kato, I., Tanaka, K., Yokokura, T Lactic acid bacterium potently induces the production of interleukin-12 and interferon-y by mouse splenocytes. Int J Immunopharmacol 1999, 21: 12131.
  62. Madsen, K.L., Doyle, J.S., Jewell, L.D., Tavernini, M.M., Fedorak, R.N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999,116: 1107-14.
  63. Konrad, A., Mahler, M., Flogerzi, B. et al. Amelioration of murine colitis by feeding a solution of lysed Escherichia coli. Scand J Gastroenterol 2003, 38: 172-9.
  64. Coconnier, M.H., Lievin, V., Hemery, E., Servin, A. L. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol 1998, 64: 4573-80.
  65. Hudault, S., Lievin, V., Bernet-Camard, M.F., Servin, A.L. Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium G5 infection. Appl Environ Microbiol 1997, 63: 513-8.
  66. Fukushima, Y, Kawata, Y., Mizumachi, K., Kurisaki, J., Mitsuoka, T Effect of bifidobacteria feeding on fecal flora and production of immunoglobulins in lactating mouse. Int J Food Microbioi 1999, 46: 193-7.
  67. Chiang, B.L., Sheih, YH., Wang, L.H., Liao, C.K., Gill, H.S. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): Optimization and definition of cellular immune responses. Eur J Clin Nutr 2000, 54: 849-55.
  68. Dieleman, L.A., Goerres, M.S., Arends, A. et a!. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003, 52: 370-6.
  69. Fukushima, Y., Kawata, Y., Hara, H., Terada, A., Mitsuoka, T. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998, 42: 39-44.
  70. Ishikawa, H., Akedo, I., Umesaki, Y., Tanaka, R., Imaoka, A., Otani, T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coli Nutr 2003; 22: 56-63.
  71. Famularo, G., Trinchieri, V., De Simone, C. Inflammatory bowel disease. N Engl J Med 2002; 347: 1982-4; author reply 1982-4.
  72. Madsen, K.L., Malfair, D., Gray, D., Doyle, J.S., Jewell, L.D., Fedorak, R.N. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 1999, 5: 262-70.
  73. Haller, D., Bode, C., Hammes, w.P., Pfeifer, A.M., Schiffrin, E.J., Blum, S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 2000, 47: 79-87.
  74. Madsen, K., Cornish, A., Soper, P. et a!. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121: 580-91.
  75. Heinemann, C., van Hylckama Vlieg, J.E., Janssen, D.B., Busscher, H.J., van der Mei, H.C., Reid, G. Purification and characterization of a surface-binding protein from Lactobacillus fermentum RG-14 that inhibits adhesion of Enterococcus faecalis 1131. FEMS Microbiol Lett 2000, 190: 177-80.
  76. Arunachalam, K., Gill, H.S., Chandra, R.K. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr 2000, 54: 263-7.
  77. Newberry, R.D., Stenson, W.F., Lorenz, R.G. Gyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med 1999, 5: 900-6.
  78. Aderem, A., Ulevitch, R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406: 782-7.
  79. Abreu, M.T., Taylor, KD., Lin, Y.C. et a!. Mutations in NOD2 are associated with fibrostenosing disease in patients with Grohn's disease. Gastroenterology 2002, 123: 679-88.
  80. da Silva Correia, J., Soldau, K., Christen, U., Tobias, P.S., Ulevitch, R.J. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. Transfer from GD14 to TLR4 and MD-2. U Bioi Chem 2001, 276: 21129-35.
  81. Jiang, 0., Akashi, S., Miyake, K., Petty, H.R. Lipopolysaccharide induces physical proximity between GD14 and Toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-I\B. J Immunol 2000, 165: 3541-4.
  82. Abreu, M.T., Vora, P., Faure, E., Thomas, L.S., Arnold, E.T., Arditi, M. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Imo munol 2001,167: 1609-16.
  83. Murch, S.H. The immunologic basis for intestinal food allergy. Curr Opin Gastroenterol 2000, 16: 552-7.
  84. Hemmi, H., Takeuchi, 0., Kawai, T. et a!. A ToIIlike receptor recognizes bacterial DNA. Nature 2000, 408: 740-5.
  85. Hacker, H., Vabulas, R.M., Takeuchi, 0., Hoshino, K., Akira, S., Wagner,.H. Immune cell activation by bacterial GpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF) 6. J Exp Med 2000, 192: 595-600.
  86. Chu, R.S., Targoni, O.S., Krieg, A.M., Lehmann, P.V., Harding, C.V. GpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th 1) immunity. J Exp Med 1997, 186: 1623-31.
  87. Roman, M., Martin-Orozco, E., Goodman, J.S. et a!. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997,3: 849-54.
  88. Martin-Orozco, E., Kobayashi, H., Van Uden, J., Nguyen, M.D., Kornbluth, R.S., Raz, E. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immuno11999, 11: 1111-8.
  89. Horner, A.A., Raz, E. Immunostimulatory-sequence DNA is an effective mucosal adjuvant. Curr Top Microbiol Immunol 2000, 247: 185-98.
  90. Wagner, H. Bacterial GpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999, 73: 329-68.
  91. Rachmilewitz, D., Karmeli, F., Takabayashi, K. et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002, 122: 1428-41.
  92. Desreumaux, P., Colombel, J.F. Intestinal flora and Grohn's disease. Ann Pharm Fr 2003, 61: 276-81.
  93. Madsen, K., Jijon, H., Yeung, H., McKaigney, C., De Simone, C. DNA from probiotic bacteria exerts anti-inflammatory actions on intestinal epithelial cells by inhibition of NF-KB. Gastroenterology 2002, 122 (Suppl. 1): A64.
  94. Jacobsen, C.N., Rosenfeldt Nielsen, V., Hayford, A.E. et al. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol 1999, 65: 4949-56.
  95. Granato, D., Perotti, F., Masserey, I. et al. Gell surface-associated lipoteichoic acid acts as an adhesion factor for attachment of Lactobacillus johnsonii La 1 to human enterocyte-like Gaco-2 cells. Appl Environ Microbiol 1999, 65: 1071-7.
  96. Wunderlich, P.F., Braun, L., Fumagalli, I. et al. Double-blind report on the efficacy of lactic acid- producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res 1989, 17: 333-8.
  97. Raza, S., Graham, S.M., Allen, S.J., Sultana, S., Cuevas, L., Hart, C.A. Lactobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan. Pediatr Infect Dis J 1995, 14: 107-11.
  98. Van Niel, C.w., Feudtner, C., Garrison, M.M., Christakis, D.A. Lactobacillus therapy for acute infectious diarrhea in children: A metaanalysis. Pediatrics 2002, 109: 678-84.
  99. Bishop, R. Ruth Bishop: Rotaviruses and vaccines. Interview by Amanda Tattam. Lancet 1999, 353: 1860.
  100. Isolauri, E., Kaila, M., Mykkanen, H., Ling, W.H., Salminen, S. Oral bacteriotherapy for viral gastroenteritis. Dig Dis Sci 1994, 39: 2595-600.
  101. Duffy, L.C., Zielezny, M.A., Riepenhoff-Talty, M. et al. Effectiveness of Bifidobacterium bifidum in mediating the clinical course of murine rota virus diarrhea. Pediatr Res 1994, 35: 690-5.
  102. Qiao, H., Duffy, L.C., Griffiths, E. et al. Immune responses in rhesus rotavirus-challenged BALB/c mice treated with bifidobacteria and prebiotic supplements. Pediatr Res 2002, 51: 750-5.
  103. Campieri, M., Gionchetti, P. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 1999, 116: 1246-9.
  104. Gibson, G.R., Roberfroid, M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J Nutr 1995,125: 1401-12.
  105. Venturi, A., Gionchetti, P., Rizzello, F. et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment PharmaGol Ther 1999, 13: 1103-8.
  106. Guslandi, M., Giollo, P., Testoni, P.A. A pilottrial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003, 15: 697-8.
  107. Katz, J.A. Prevention is the best defense: Probiotic prophylaxis of pouchitis. Gastroenterology 2003, 124: 1535-8.
  108. Gionchetti, P., Rizzello, F., Venturi, A. et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 2000, 119: 305-9.
  109. Gionchetti, P., Rizzello, F., Helwig, U. et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 2003, 124: 1202-9.
  110. Kuisma, J., Mentula, S., Jarvinen, H., Kahri, A., Saxelin, M., Farkkila, M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003,17:509-15.
  111. Campieri, M., Rizzello, F., Venturi, A. et al. Gombination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Grahn's disease: A randomized controlled study vs Mesalamine. Gastroenterology 2000, 118: A781.
  112. Guandalini, S. Use of Lactobacillus-GG in paediatric Grohn's disease. Dig Liver Dis 2002, 34 (Suppl. 2): S63-5.
  113. Prantera, C., Scribano, M.L. Probiotics and Grohn's disease. Dig Liver Dis 2002, 34 (Suppl. 2): S66-7.
  114. Niedzielin, K., Kordecki, H., Birkenfeld, B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001, 1 3: 1143- 7 .
  115. Madden, J.A., Hunter, J.O. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 2002, 88 (Suppl. 1): S67-72.
  116. Bazzocchi, G., Gionchetti, P., Almerigi, P.F., Amadini, C., Campieri, M. Intestinal micro flora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 2002, 34 (Suppl. 2): S48-53.
  117. King, TS., Elia, M., Hunter, J.O. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998, 352: 1187-9.
  118. Spiller, R.C., Jenkins, D., Thornley, J.P. et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000,47: 804-11.
  119. Brigidi, P., Vitali, B., Swennen, E., Bazzocchi, G., Matteuzzi, D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001, 152: 735-41 .
  120. Kim, H.J., Camilleri, M., McKinzie, S. et al. A randomized controlled trial of a probiotic, VSL3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17: 895-904.
  121. Mastretta, E., Longo, P., Laccisaglia, et al. Effect of Lactobacillus GG and breast-feeding in the prevention of rota virus nosocomial infection. J Pediatr Gastroenterol Nutr 2002; 35: 527 -31.
  122. Guandalini, S., Pensabene, L., Zikri, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: A multicenter European trial. J Pediatr Gastroenterol Nutr 2000; 30: 54-60.
  123. Kirjavainen, P.V., Salminen, S.J., Isolauri, E. Probiotic bacteria in the management of atopic disease: Underscoring the importance of viability. J Pediatr Gastroenterol Nutr 2003; 36: 223-7.
  124. Katelaris, P.H., Salam, I., Farthing, M.J. Lactobacilli to prevent traveler's diarrhea? N Engl J Med 1995; 333: 1360-1.
  125. Vanderhoof, J.A., Whitney, D.B., Antonson, D.L., Hanner, TL., Lupo, J.V., Young, R.J. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999; 135: 564-8.
  126. Surawicz, C.M., Elmer, G.W., Speelman, P., McFarland, LV, Chinn, J., van Belle, G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study. Gastroenterology 1989; 96: 981-8.
  127. McFarland, LV, Surawicz, C.M., et al. Prevention of beta-Iactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90: 439-48.:'"
  128. Surawicz, C.M., McFarland, LV., Elmer, G., Chinn, J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 1989; 84: 1285-7.
  129. Gorbach, S.L., Chang, TW, Goldin, B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; 2: 1519.
  130. Biller, JA, Katz, A.J., Flores, A.F., Buie, TM., Gorbach, S.L. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995; 21: 224-6.
  131. Prantera, C., Scribano, M.L., Falasco, G., Andreoli, A., Luzi, C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-9.
  132. Biancone, L., De Nigris, F., Del Vecchio Blanco, et al. Lactobacillus GG is not effective in subsiding bowel tenderness in inactive Crohn's disease. Gastroenterology 2003: T1402A.
  133. Vanderhoof, J.A., Young, R.J. Role of probiotics in the management of patients with food allergy. Ann Allergy Asthma Immunol 2003; 90: 99-103.
  134. Isolauri, E., Arvola, T, Sutas, Y, Moilanen, E., Salminen, S. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30: 1604-10.
  135. Kalliomaki, M., Salminen, S., Arvilommi, H., Kero, P., Koskinen, P., Isolauri, E. Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial. Lancet 2001; 357: 1076-9.
  136. Kalliomaki, M., Salminen, S., Poussa, T., Arvilommi, H., Isolauri, E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361: 1869-71.
  137. Ibnou-Zekri, N., Blum, S., Schiffrin, E.J., Von Der Weid, T. Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro. Infect Immun 2003, 71: 428-36.
  138. Coakley, M., Ross, R.P., Nordgren, M., Fitzgerald, G., Devery, R., Stanton, C. Conjugated linoleic acid biosynthesis by human-derived Bifidobacterium species. J Appl Microbiol 2003, 94: 138-45.
  139. Steidler, L., Hans, w., Schotte, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-1O. Science 2000, 289: 1352-5.
  140. Seegers, J.F. Lactobacilli as live vaccine delivery vectors: Progress and prospects. Trends Biotechnol 2002, 20: 508-15.


VSL3 Probiotic live lactic acid bacteria
VSL3# Probiotic
Clinical Trials
Help Ulcerative Colitis
Why VSL#3?
Dr Ohhira's OMX12+ lactic acid Probiotic from Essential Formulas
Probiotic OMX12+:
Dr Ohhira's Award Winning
lactic acid probiotic Formula

Primal Defense HSO Probiotic from Garden of Life
Garden of Life
Primal Defense Capsules:
Probiotic with HSOs

Culturelle Lactobacillus GG
Culturelle
Lactobacillus GG
Relieve digestive
complaints

Multi Acidophilus from Natural Factors with E Faecium
Multi Acidophilus
with E Faecium